Bevacizumab May Differentially Improve Ovarian Cancer Outcome in Patients with Proliferative and Mesenchymal Molecular Subtypes
Abstract
Purpose: Recent progress in understanding the molecular biology of epithelial ovarian cancer has not yet translated into individualized treatment for these women or improvements in their disease outcome. Gene expression has been utilized to identify distinct molecular subtypes, but there have been no reports investigating whether or not molecular subtyping is predictive of response to bevacizumab in ovarian cancer.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jul 13, 2017
- Source ID
- 10.1158/1078-0432.ccr-16-2196
Entities
People
- Alexander Burges
- Andreas Du Bois
- Andrew C. Embleton
- Ann L Oberg
- Boris Winterhoff
- Chen Wang
- Craig April
- Ellen L Goode
- Felix Hilpert
- Friedrich Kommoss
- Gottfried E. Konecny
- Jacobus Pfisterer
- Jeremy Chien
- Jian-bing Fan
- Klaus Baumann
- Lynn C. Hartmann
- Mahesh Parmar
- Matthew J. Maurer
- Richard Kaplan
- Sean C. Dowdy
- Shaun M. Riska
- Stefan Kommoss
- Sven Mahner
- Timothy Perren
- Ulrich Canzler
- Viji Shridhar
- Willibald Schroeder
Organizations
- Mayo Clinic
- Technische Universität Dresden
- United States Department of Defense
- University College London
- University of California, Los Angeles
- University of Kansas
- University of Leeds
- University of Marburg
- University of Minnesota